SlideShare for iOS
by Linkedin Corporation
FREE - On the App Store
The intersection of opioid use and HIV is well documented. More than one-third of all AIDS cases in the U.S. are directly or indirectly linked to injection drug use. Additionally, dependence and abuse ...
The intersection of opioid use and HIV is well documented. More than one-third of all AIDS cases in the U.S. are directly or indirectly linked to injection drug use. Additionally, dependence and abuse of pain relievers is on the rise; people living with HIV/AIDS who suffer from chronic pain may be at particular risk. Opioids are highly addictive and mortality among illicit opioid users is estimated at 13 times that of the general population. The SPNS Buprenorphine Initiative investigated the effectiveness of integrating buprenorphine opioid abuse treatment into HIV primary care settings.
This Webcast is the first in a series under the new SPNS Integrating HIV Innovative Practices project (www.careacttarget.org/ihip) to assist providers in replicating SPNS work in their sites. This Webcast will introduce providers to the SPNS Buprenorphine Initiative, its findings, its synergy with the National HIV/AIDS Strategy, and provide an overview of opioid use and HIV.
The subsequent Webcast in the series will examine the clinical aspects of buprenorphine therapy, best practices, and implementation guidance. See also Integrating Buprenorphine Therapy Into HIV Primary Care Settings, a monograph on best practices, available at: https://careacttarget.org/content/integrating-buprenorphine-therapy-hiv-primary-care-settings.